Corpus ID: 8087044

XP-828 L in the Treatment of Mild-to-Moderate Psoriasis : A Randomized , Double-blind , Placebo-controlled Study

@inproceedings{Poulin2007XP828LI,
  title={XP-828 L in the Treatment of Mild-to-Moderate Psoriasis : A Randomized , Double-blind , Placebo-controlled Study},
  author={Yves P Poulin and Robert Bissonnette and Christina L. Juneau and Kim Cantin and Rejean Drouin and Patrice E Poubelle},
  year={2007}
}
Advitech is the developer of XP-828L. Abstract Background: XP-828L, a protein extract obtained from sweet whey, has demonstrated potential benefit for the treatment of mild to moderate psoriasis in an open-label study. Objective: To study in a randomized, double-blind, placebo-controlled study the safety and efficacy of XP-828L in the treatment of mild to moderate psoriasis. Design: XP-828L 5 g/d (group A, n=42) or placebo (group B, n=42) was given orally for 56 days followed by XP-828L 5 g/d… CONTINUE READING

Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

Figures and Tables from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Milk casein - 25 . based diet containing TGF - beta controls the inflammatory reaction in the HLA - B 27 transgenic rat

  • EJ Schiffrin, ME Yousfi, EP FaureM
  • JPEN J Parenter Enteral Nutr
  • 2005

Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment

  • Feldman, GG Krueger
  • J Am Acad Dermatol
  • 2004

Immunosupressive effect of a milk - derived extract [ abstract ]

  • N Aattouri, SF Gauthier, M Santure
  • Clin Invest Med
  • 2004

Therapeutic applications of whey protein . 8

  • K Marshall
  • Altern Med Rev
  • 2004

transforming growth factor beta 2 containing nutritional support formula in a murine model of inflammatory bowel disease

  • EJ Schiffrin, ME Yousfi, M EPFaure
  • J Am Coll Nutr
  • 2004